AgriGenome Labs Pvt Ltd

AgriGenome Labs (AgGenome) was started in 2013 as a division of SciGenom Labs and after successful incubation, it became an independent company in 2015 with facilities in Genome Valley, Hyderabad and "SmartCity Kochi"​, Cochin. Both the facilities are equipped with state-of-the-art instruments and provide genome sequencing, editing and bioinformatics services for Plant, Animal & Microbial projects of the industry as well as academic and government institutions. AgGenome genomics platforms include PacBio Sequel (first installation in Asia), Illumina sequencers, ABI 3730xl Sanger sequencers and more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

HISTOSONICS ANNOUNCES AGREEMENT WITH GE HEALTHCARE

HistoSonics | May 24, 2022

news image

HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare's LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of HistoSonics' novel sonic beam therapy. As part of the agreement and upon market authorization, HistoSonics will distribute GE Healthcare's LOGIQ E10 Series on a one-to-one basis with its breakthrough liver th...

Read More

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

news image

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More

PHARMABCINE EXPANDS PARTNERSHIP WITH SAMSUNG BIOLOGICS FOR PMC-403

PharmAbcine Inc. | September 21, 2020

news image

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders. Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support. PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibo...

Read More

MEDGENOME TO INVESTMENT $55M LED BY LEAPFROG INVESTMENTS

Express Healthcare | April 02, 2020

news image

The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...

Read More
news image

MEDICAL

HISTOSONICS ANNOUNCES AGREEMENT WITH GE HEALTHCARE

HistoSonics | May 24, 2022

HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare's LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of HistoSonics' novel sonic beam therapy. As part of the agreement and upon market authorization, HistoSonics will distribute GE Healthcare's LOGIQ E10 Series on a one-to-one basis with its breakthrough liver th...

Read More
news image

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More
news image

PHARMABCINE EXPANDS PARTNERSHIP WITH SAMSUNG BIOLOGICS FOR PMC-403

PharmAbcine Inc. | September 21, 2020

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders. Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support. PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibo...

Read More
news image

MEDGENOME TO INVESTMENT $55M LED BY LEAPFROG INVESTMENTS

Express Healthcare | April 02, 2020

The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...

Read More